Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tropisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 9/20 | 1.00 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 7/20 | 1.00 |
| ▸ | HTR3B known ✓ | O95264 | 7/20 | 1.00 |
| ▸ | HTR3D known ✓ | Q70Z44 | 7/20 | 1.00 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 2/20 | 1.00 |
| ▸ | CHRNG | P07510 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 2/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 2/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 2/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 2/20 | 1.00 |
| ▸ | CHRND | Q07001 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tropisetron SCHEMBL18297 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL29405651 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL3953452 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL17766649 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL31061471 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL463128 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL29930627 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL6273985 | 0.99 | APEX1 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL669358 | 0.99 | APEX1 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL133873 | 0.99 | APEX1 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20625 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260130929-A1 | USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST | SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4719497-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | Rayzebio, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4719552-A1 | INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-12594270-B2 | Schizophrenic disorder treatment using combination therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2026-04-07 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| CN-1201390-A | 5-HT3 receptor antagonists for treating dyskinesia | GLAXO WELLCOME INC (GB) | 1998-12-09 | — | — | CN | claimed |
| WO-1998053815-A1 | TRANSDERMAL DRUG DELIVERY DEVICE FOR THE DELIVERY OF TROPISETRON OR GRANISETRON | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-12-03 | — | — | WO | claimed |
| WO-1998047481-A1 | USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-29 | — | — | WO | claimed |
| EP-0851756-A1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1998-07-08 | — | — | EP | claimed |
| WO-1997047285-A1 | GASTRIC-RETENTIVE ORAL CONTROLLED DRUG DELIVERY SYSTEM WITH ENHANCED RETENTION PROPERTIES | DEPOMED, INC. (US) | 1997-12-18 | — | — | WO | claimed |
| WO-1997018801-A1 | PHARMACEUTICAL FORMULATION | EURO-CELTIQUE S.A. (LU) | 1997-05-29 | — | — | WO | claimed |
| WO-1997010823-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1997-03-27 | — | — | WO | claimed |
| US-5576317-A | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis | PFIZER INC. (US) | 1996-11-19 | — | — | US | claimed |
| CN-1132625-A | NK-1 receptor antagonits and 5HT3 receptor antagonists for treatment of emesis | PFIZER (US) | 1996-10-09 | — | — | CN | claimed |
| EP-0715855-A2 | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis | PFIZER INC. (US) | 1996-06-12 | — | — | EP | claimed |